Regorafenib is an oral multi-kinase inhibitor with antiangiogenic activity against VEGFR2 that was FDA approved in 2017 as second-line therapy for advanced HCC based on results reported from the international, multicenter randomized phase III RESORCE clinical trial [6]. The gene discussed is KDR; the disease is hepatocellular carcinoma.